Shionogi & Co., Ltd.
Notice on Completion of Transfer of Edaravone Business and Establishment of Radicava Business Company
Completed the transfer of rights for the Edaravone business from Tanabe Pharma effective April 1, 2026, and established the Radicava business company. Annual sales revenue of approximately 700 million USD expected from fiscal year 2026.
Key Figures
- Radicava U.S. Sales Revenue (Fiscal Year Ending March 2025): 94,491 million JPY
- Number of Employees at Radicava Business Company: 143 persons
- Projected Global Sales Revenue for Fiscal Year 2026: Approximately 700 million USD
AI要約
Overview of M&A
Shionogi & Co., Ltd. completed the transfer of all rights, including intellectual property rights and sales rights in major countries and regions, for the amyotrophic lateral sclerosis (ALS) treatment drug Edaravone business from Tanabe Pharma Corporation effective April 1, 2026. Accordingly, the newly established Radicava business company in the U.S. (RADIANCE NEWCO, LLC) has commenced operations as a wholly owned subsidiary of Shionogi Inc. Edaravone is a free radical scavenger effective in slowing the progression of ALS, with both injection and oral suspension forms approved in the U.S., where sales revenue reached 94,491 million JPY for the fiscal year ending March 2025.
Future Outlook
The impact on consolidated financial results from the fiscal year ending March 2027 is currently under detailed review, but the business is expected to contribute to revenue and profit starting from the fiscal year ending March 2027. With the transfer of the Edaravone business, Shionogi aims to establish a global business foundation in the rare disease field and provide continuous and stable treatment to patients. Sales revenue of approximately 700 million USD is expected globally for fiscal year 2026.
